In one paragraphArticle in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
17 authors.
Son N NguyenMass Spectrometry Facility, University of Massachusetts Chan Medical School, Shrewsbury, MA, USA.ORCID 0000-0002-6563-1685 Sean D MannDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Prakruthi VadakattuDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Zhengrong ZhangDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Nibedita Basu RayDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Angela DuongInstitute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA, USA.
Tony TuckDepartment of Pharmacology, Physiology & Biophysics, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.
Julia TcwDepartment of Pharmacology, Physiology & Biophysics, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.ORCID 0000-0002-3054-9374 Alison M GoateDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0002-0576-2472 Celeste M KarchHope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0002-6854-5547 Scott A ShafferMass Spectrometry Facility, University of Massachusetts Chan Medical School, Shrewsbury, MA, USA.ORCID 0000-0002-5264-3257 Seiko IkezuDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Maria Paz Gonzalez-PerezMass Spectrometry Facility, University of Massachusetts Chan Medical School, Shrewsbury, MA, USA.ORCID 0000-0001-7354-367X Wayne W PoonInstitute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA, USA.ORCID 0000-0003-0625-3968 Funding
Project 4 (Genetic modifiers for APOE-associated Alzheimer's disease pathogenesis)U19AG069701 · NIA · MAYO CLINIC JACKSONVILLE · PI ALISON M GOATE · 2021 to 2026
$42.0MResearch Education ComponentP30AG066444 · NIA · WASHINGTON UNIVERSITY · PI Susan Lynn Stark · 2020 to 2026
$28.7MTargeting the miR-155 and APOE-TREM2 pathways to restore dysfunctional microglia in Alzheimer’s diseaseR01AG054672 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI BUTOVSKY, OLEG, IKEZU, TSUNEYA · 2017 to 2021
$4.1MElucidating endolysosomal trafficking dysregulation induced by APOE4 in human astrocytesR01AG082362 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Julia TCW · 2023 to 2026
$3.3MMicroglia targeted interventions in prodromal Alzheimer's disease stageR01AG083941 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Julia TCW · 2023 to 2026
$3.2MMolecular characterization of extracellular vesicles for the spread of misfolded tau proteinR01AG067763 · NIA · MAYO CLINIC JACKSONVILLE · PI IKEZU, TSUNEYA · 2021 to 2025
$3.1MAssessment of a novel tau propagation pathway from layer II medial entorhinal cortical neurons to CA1 pyramidal neurons as an early Braak stage mouse modelR01AG072719 · NIA · MAYO CLINIC JACKSONVILLE · PI IKEZU, TSUNEYA · 2021 to 2025
$2.7MTherapeutic evaluation of targeting Tau Tubulin kinase-1 in Alzheimer’s diseaseR01AG079859 · NIA · MAYO CLINIC JACKSONVILLE · PI Seiko Ikezu · 2023 to 2026
$2.2MTargeting emerging P2RX7 signaling pathways in animal models of Alzheimer's diseaseR01AG066429 · NIA · MAYO CLINIC JACKSONVILLE · PI IKEZU, TSUNEYA · 2020 to 2024
$2.0MAPOE and microglia-mediated progression in tau pathology in ADR01AG054199 · NIA · MAYO CLINIC JACKSONVILLE · PI IKEZU, TSUNEYA · 2024 to 2025
$1.4MNIA NIH HHS P30 AG066444NIA NIH HHS R01 AG054199NIA NIH HHS R01 AG054672NIA NIH HHS R01 AG066429NIA NIH HHS R01 AG067763NIA NIH HHS R01 AG072719NIA NIH HHS R01 AG079859NIA NIH HHS R01 AG082362NIA NIH HHS R01 AG083941NIA NIH HHS U19 AG069701
6 · The paper itselfAbstract
The apolipoprotein E ε4 (
Identifiers
PMID42818533
PMCPMC13622849
What OpenQuestion holds
Textmetadata
Read underepoch 390